Every investment until its FDA approved carries a risk, best of the best as well. Even Clarity Pharma has a risk associated with it.
The question if it can be a $10 per share company is dependent on the outcome.
If successful results and FDA approved, hell yes. Without a doubt. Our TAM is bigger than NEU and we will DKD and COPD in the ranks.
With 2 deals in the bag, 1st interim analysis cleared, 2 big US and China deals to come, the more appropriate question to ask is if at 0.6c, the risk reward ratio attractive enough to buy it.
DXB - Research & Valuation, page-201
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $253.1M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 45.5¢ | $1.771M | 3.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34765 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 26998 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |